结果：序贯内分泌治疗组3，5年总生存率（OS）为80.0%（41/51）和74.5%(38/51)，3，5年无病生存率（DFS）分别为74.5%（38/51）和60.7%（31/51），对照组的3，5年的OS分别为 60.9%（28/46）、50.0%（23/46），3，5年DFS 分别为52.2%（24/46）和39.1%（18/46）。上述各生存率治疗组均明显高于对照组（均P＜0.05）。
Objective：To explore the effect of sequential endocrine therapy in breast cancer patients whose expression of ER and PR was negative preoperatively and was converted to positive by neoadjuvant chemotherapy (NAC).
Methods：The clinical study was carried out in 97 cases of breast cancer whose ER and PR statue were converted from negative to positive after NAC. after NAC the 97 cases were divided into sequential endocrine therapy group and control group. The sequential endocrine group was treated with TAM 10mg Bid for 5 years, the control group was treated with placebo.
Results： In sequential endocrine treatment group, the 3-and 5-year disease-free survival was 74.5%(38/51) and 60.7%(31/51) respectively, and the 3-and 5-year overall survival was 80%(41/51) and 74.5%(38/51) respectively. In control group, the 3-and 5-year disease-free survival was respectively 52.2%(24/46) and 39.1%(18/46), and the 3-and 5-year overall survival was respectively 60.9%(28/46) and 50.0%(23/46). The corresponding values were significantly higher in sequential endocrine therapy group than in control group.
Conclusions： The disease-free and overall survival are significantly increased by applying sequential endocrine therapy in breast cancer patients whose expression of ER and PR has been converted from negative to positive by neoadjuvant chemotherapy.
管小青| 吴骥| 陈焰| 顾书成| 吴建强| 吴际生| 袁牧| 江小玲| 侍孝红| 葛立峰.新辅助化疗后ER、PR由阴性转为阳性乳腺癌患者的序贯内分泌治疗[J].中国普通外科杂志,2010,19(11):1196-1199.